Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

BACKGROUND: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with poor prognosis. Up to now, no targeted treatment beyond anti-VEGF therapy has been approved for TNBC and cytotoxic agents remain the mainstay of treatment. Ixazomib is a s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Petzer, Andreas, Burgstaller, Sonja, Fuchs, David, Rossmann, Dieter, Balic, Marija, Egle, Daniel, Rumpold, Holger, Singer, Christian F., Bartsch, Rupert, Petru, Edgar, Melchardt, Thomas, Ulmer, Hanno, Mlineritsch, Brigitte, Greil, Richard
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2018
Schlagworte:
Study Protocol
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220453/
https://ncbi.nlm.nih.gov/pubmed/30400780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4979-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge